Journal of Immunology Research / 2012 / Article / Tab 1

Review Article

The Tumor Necrosis Factor Superfamily of Cytokines in the Inflammatory Myopathies: Potential Targets for Therapy

Table 1

Tumor necrosis factor inhibitors for treating inflammatory myopathies: published trial results for infliximab and etanercept.

Compound and treatment regimenDiagnosis/patients continued to end pointFollow-up timeClinical outcome at end pointReference

infliximab 6 mg/kg 4-weekly or more frequentR-JDM/532 to 130 weeksI (5/5)[19]
infliximab 10 mg/kg (week 0, 2, 6, 14)R-DM/1
R-PM/4
R-IBM/4
16 weeksNC (1/1)
I (2/4) W (2/4)
I (1/4) NC (3/4)
[20]
infliximab 10 mg/kg (week 0, 2, 4)R-DM/1
R-PM/1
12 weeksI (1/1)
I (1/1)
[21]
infliximab 10 mg/kg (week 20)
infliximab 10 mg/kg (week 14, 18, 22)
R-DM/1
R-PM/1
66 weeksI (1/1)
I (1/1)
[22]
infliximab 10 mg/kg (week 0, 2, 6, 14, 22)PM/226 weeksI (2/2)[23]
infliximab 8 mg/kg (week 0, 2, 6)R-DM/16 weeksI (1/1)
infliximab 10 mg/kg (week 0, 2, 4, 6, 9)R-PM/169 weeksI (1/1)[24]
infliximab 3 mg/kg (week 0, 2, 6, every 8) and etanercept 25 mg twice weeklyR-DM/1
R-PM/2
36 to 96 weeksPR (1/1)
I (2/2)
[25]
etanercept 25 mg twice weeklyR-DM/156 weeksI (1/1)[26]

Abbreviations: dermatomyositis (DM), improved (I), inclusion body myositis (IBM), juvenile DM (JDM), no change (NC), partial response (PR), polymyositis (PM), refractory DM/PM/IBM (R-DM/PM/IBM), worsened (W).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.